Palvella Therapeutics, Inc.
Quick facts
Phase 3 pipeline
- PTX-022 · Oncology
PTX-022 is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) designed to modulate immune cell function and tumor microenvironment. - QTORIN 3.9% rapamycin anhydrous gel · Dermatology
QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Palvella Therapeutics, Inc.
What is Palvella Therapeutics, Inc.'s pipeline?
Palvella Therapeutics, Inc. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include PTX-022, QTORIN 3.9% rapamycin anhydrous gel.
Related
- Sector hub: All tracked pharma companies